

## “Genetic Testing and Research for CdLS ”

### CdLS Meeting, Pesaro, Italy, 2017



**Ian D. Krantz, M.D.**  
**The Children's Hospital of Philadelphia and**  
**The Perelman School of Medicine at the University of Pennsylvania**

## The general reaction to genetics.....



## Genetic/Genomic Tests

- All are asking the same question:


*Is there a change in the DNA that is causing or contributing to the observed clinical findings in an individual?*

## Types of Genetic Testing


- Chromosome Analysis
- Fluorescence in situ hybridization
- Single gene
  - » PCR single locus & multiplex PCR
  - » Southern blot
  - » Sanger sequencing
- Chromosomal Microarray Analysis
- MLPA & aCGH for dup/del of single exons
- Next generation sequencing based
  - » Panels
  - » Exomes
  - » Genomes






# Genetics/Genomics 101



## The Central Dogma:







**Male - 46,  
XY****2 copies of all  
genetic material!****Female - 46,  
XX****2 copies of all  
genetic material!**


## Chromosomal Microarray Analysis (CMA)

### Two Primary Methods

- Comparative Genomic Hybridization (“CGH”)
  - SNP based testing
- High resolution – can detect very small deletions and duplications



## Simplified structure of a gene




## Sequencing Based Tests

- Sanger sequencing
  - Targeted regions-single gene
- Next Generation Sequencing (NGS)

## Sanger Sequencing

Gold standard for single gene testing

Sequence one genetic region at a time



## Sanger sequencing: when to order

- R/O mutations in specific genes based on clinical phenotype
- Limitation:
  - You have to know what you're looking for

## Next Generation Sequencing - NGS (2005)

### Scalability, Speed, Resolution



## NGS Tests

### (Massively parallel sequencing)

- Targeted gene panels
  - Collection of genes relevant to a phenotype
- Exome Sequencing
- Genome Sequencing

## Targeted Gene Panels

### Advantages

- Selected genes with clinical utility
- Complete sequencing of genes of interest
- Cost effective and fast

### Limitations

- Adding new genes lags behind discovery
- Upgrade to content = continuous validation
- Diagnosis missed if not on the gene list

## NextGen Sequencing



### Genome sequencing

- 3 billion base pairs
- 12 million variants per individual
- Advantage: sequence everything
- Disadvantage: expensive, lower fold coverage, data storage, interpretation



### Exome sequencing

- 30 Million base pairs (1% of genome)
- 20,000 genes made up of ~180,000 exons
- 50-100,000 variants per exome
- Advantage: higher fold coverage, less expensive
- Disadvantage: incomplete capture

Nancy Spinner, PhD, Ian Krantz, MD



## Exome Sequencing: When to Order

- Suspect genetic etiology
- Differential diagnosis → non overlapping disorders
- Genetic heterogeneity (lots of genes)
- Previous genetic testing negative


## Targeted Testing: e.g. Single gene testing




## Genomic level testing: Chromosomal Microarray, Exome/Genome Sequencing



### Mutation



## Polymorphisms (“poly” **many** “morphe” **form**) and Variants of Uncertain Significance (VUS)




### Autosomal Dominant Inheritance

	<b>D</b>	d
d	<b>Dd</b>	dd
d	<b>Dd</b>	dd

If one of the parents has an AD disorder, there is a 50% recurrence risk with each subsequent pregnancy


	d	d
d	<b>Dd</b>	dd
d	dd	dd

- Often mutations in AD genes arise sporadically
- Recurrence risk ~1%
- Germ line mosaicism



Most common pattern in CdLS

Rare:



## Cornelia de Lange Syndrome (CdLS)

- First description by Vrolik in 1849
- Described by Brachmann in 1916
- Cornelia de Lange described two unrelated infants in 1933
- Prevalence as high as 1 in 10,000
- Most cases are sporadic, but rare familial recurrences occur
- Dominant inheritance with variable expressivity
- Caused by mutations in cohesin structural and regulatory proteins
- Genetically heterogeneous:

NIPBL (5p13.1) ~ 60%

SMC1A (Xp11.2) ~ 5%

HDAC8 (Xq13) ~ 2%


SMC3 (10q25) 1 case

RAD21 (8q24) ~ 1% (atypical)


unknown ~ 30%



### CdLS Multisystem Clinical Manifestations



Growth



IQ




Craniofacial



Limbs




GERD




Malrotation




Hirsutism



Ophtho



Hearing Loss



CHD



GU



CHD




Hematopoietic


## *NIPBL* (*Nipped-B Like*)





**Drs. Anne Calof and Arthur Lander**



**Dr. Dale Dorsett**



**Dr. Marcella Devoto**




**Katsu Shirahige**



## Cohesin Function

### ➤ Cohesin function:

- Sister chromatid cohesion
- Repairing double strand DNA break
- Maintaining 3-D genome organization
- cell proliferation
- maintaining pluripotency of stem cells
- gene expression



## ***NIPBL* mutations in CdLS**

Found in both Severe and Mild Variants

Found throughout gene

Truncating→more severe

Missense→milder

Overall mutation detection rate of ~ 60 %

### **Severe-55/75 (73%)**

Missense - 4 (7%)  
Nonsense - 18 (33%)  
Splicesite - 4 (7%)  
Frameshift - 29 (53%)  
In Frame Deletion - 0



### **Moderate-37/77 (48%)**

Missense - 15 (40%)  
Nonsense - 2 (5%)  
Splicesite - 7 (20%)  
Frameshift - 10 (27%)  
In Frame Deletion - 3 (8%)




### **Mild-33/71 (46%)**



Missense - 21 (64%)  
Nonsense - 0  
Splicesite - 10 (30%)  
Frameshift - 0  
In Frame Deletion - 2 (6%)




## **Cohesinopathies**


























### *Drosophila* Model of CdLS – Learning & Memory




### *Drosophila* Model of CdLS – Sleep Disturbance




## Establishment of Induced Pluripotent Stem Cells (iPSCs)







## What can a CdLS stem cell tell us?




## “Neuronal Modeling”



## CdLS Patient Derived iPSC Cardiomyocyte Lines







Dr. Kosuke Izumi








## CHOPS Syndrome

- **C** – Major: Cognitive impairment, Coarse facies,
- **H** – Major: Hear defects, Minor: Hearing loss
- **O** - Major: Obesity
- **P** – Major: Pulmonary involvement (trachea-laryngo malacia, chronic lung dis.)
- **S** - Major: Short stature, Skeletal dysplasia (brachydactyly, vertebral anomalies)

Izumi et al, Nat Genet, 2015




## Mechanistic link between CHOPS syndrome and Cornelia de Lange syndrome





## “Disorders of Transcriptional Regulation (DTRs)”


Izumi, Mol Syndromol 2016




Adapted from Yin and Wang Development 2014



**NIPBL expression in LCLs  
from 16 normal controls and 15 CdLS patients**




**~ 1.38 fold**  
 **$p = 9.38E -09$**



***'Regarding every disease now incurable, we may entertain the hope - faint it may be with respect to some, stronger in the case of others - that our powerlessness may not be permanent, and that we, or those who come after us, may be able to speak in very different terms.'***

**William R. Gowers, M.D.,  
1849-1915**



### **Acknowledgements - CdLS**

#### **Children's Hospital of Philadelphia**

Laird Jackson  
Sarah Noon  
Maninder Kaur  
Matthew Deardorff  
Yaning Wu  
Jay Mills  
Kosuke Izumi  
Marcella Devoto  
Zhe Zhang  
Donna Berroddin  
Pamela Herrera  
Olivia Katz  
Devanshi Mehta  
Chiara Bettale

#### **Saint Louis University**

Dale Dorsett  
Ziva Misulovin

#### **UCI**

Anne Calof  
Arthur Lander  
Thomas Schilling

#### **University of Tokyo**

Katsuhiko Shirahige

#### **Italy**

Angelo Selicorni  
Antonio Musio



**CdLS-USA Foundation**  
Cornelia de Lange Syndrome Foundation, Inc.



**Children's Hospital  
of Philadelphia**

CENTER FOR CORNELIA DE LANGE  
SYNDROME & RELATED DIAGNOSES





And those to whom we are most indebted....